Hyperion's Ravicti beats 2Q estimates, but shares down 10%
This article was originally published in Scrip
Executive Summary
The first full quarter of sales for the Hyperion Therapeutics drug Ravicti (glycerol phenylbutyrate) exceeded expectations in the second quarter, but the South San Francisco-based company's stock still closed down 10% at $22.41 per share on 15 August.